Skip to main content
. 2010 Mar;176(3):1525–1541. doi: 10.2353/ajpath.2010.090909

Figure 6.

Figure 6

Reversibility of M. pulmonis burden and leukocyte influx by dexamethasone. Bar graphs of expression of M. pulmonis 16S rRNA in tracheas by qRT-PCR (A), total RNA yield per trachea (B), lung weight (C), and bronchial lymph node weight (D) from pathogen-free mice and mice infected for 14 days and untreated or infected for 14 days followed by treatment with vehicle or with dexamethasone for 14 days or 28 days. Lung and bronchial lymph node weights are normalized to the corresponding final body weights *P < 0.05 versus pathogen-free mice; **P < 0.05 versus 14-day infected baseline group before dexamethasone treatment; ***P < 0.05 versus corresponding infected, vehicle-treated controls (n = 10 to 15 mice per group). E–J: H&E-stained sections of mouse tracheas (E–G) and mouse left lungs (H–J) in mice infected for 14 days (E and H) and in mice infected for 42 days and treated with vehicle (F and I) or dexamethasone (G and J) for the last 28 days. Arrows mark leukocyte influx in tracheal epithelial layers, and arrowheads mark leukocyte influx in tracheal mucosa. Asterisk in J marks leukocyte clusters remaining in lungs after 28 days of dexamethasone treatment. Dex, dexamethasone; B, bronchiole; V, blood vessel. Scale bars: 100 μm in (E–G); 400 μm (H–J).